Evidence map›Paper›PMID 42368624›Full record

ArticleMolecular therapy. Oncology2026

AGTR1 signaling contributes to tumor immunity and therapy response in non-small cell lung cancer.

Tatsuki Ikoma, Keigo Araki, Mai Kitagawa, Natsuno Makihara, Yutaro Nagata, Kazuki Fujii, Yukiko Okuno, Keisuke Kamisako, Yuta Okazaki, Kentaro Nakanishi and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tatsuki IkomaDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Keigo ArakiDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Mai KitagawaDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Natsuno MakiharaDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Yutaro NagataDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Kazuki FujiiDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Yukiko OkunoDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Keisuke KamisakoDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Yuta OkazakiDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Kentaro NakanishiDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Yume SanadaDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Kiyori YoshidaDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Kahori NakahamaDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Yuki TakeyasuDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Utae KatsushimaDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Yuta YamanakaDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Satoshi IkedaDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Hiroshige YoshiokaDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.
Toshio ShimizuDepartment of New Experimental Therapeutics, Kansai Medical University Hospital, 2-3-1, Shinmachi, Hirakata-city, Osaka 573-1191, Japan.
Takayasu KurataDepartment of Thoracic Oncology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata-city, Osaka 573-1010, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiotensin II receptor type 1 (

Indexed as

AGTR1angiotensin II receptor type 1angiotensin receptor blockerARBCAFscancer-associated fibroblastsICBimmune checkpoint blockadeTGF-βtransforming growth factor β

Identifiers

PMID42368624
PMCPMC13293692

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.